Advertisement

Pneumo News

, Volume 11, Issue 2, pp 23–28 | Cite as

Chemotherapie, Operation und Bestrahlung

Multimodale Therapiekonzepte beim malignen Pleuramesotheliom

  • Laura V. KlotzEmail author
  • Florian Eichhorn
  • Hauke Winter
  • Martin E. Eichhorn
fortbildung
  • 9 Downloads

Das maligne Pleuramesotheliom ist ein seltener, aggressiv wachsender Tumor der Pleura, der häufig mit einer Asbestexposition assoziiert ist. Die überwiegend männlichen Patienten haben oft Begleiterkrankungen, wodurch das Behandlungsmanagement erschwert wird. Es gibt mehrere multimodale Therapiekonzepte, die sich vor allem hinsichtlich des Umfangs und der Art einer chirurgischen Therapie unterscheiden, sofern sie dem Tumorstadium entsprechend indiziert ist.

Literatur

  1. 1.
    Opitz I. Management of malignant pleural mesothelioma-The European experience. J Thorac Dis. 2014;6 (Suppl 2):S238-52.  https://doi.org/10.3978/j.issn.2072-1439.2014.05.03Google Scholar
  2. 2.
    Ladanyi M, Zauderer MG, Krug LM et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18(17):4485–90.  https://doi.org/10.1158/1078-0432.CCR-11-2375CrossRefGoogle Scholar
  3. 3.
    Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–95.  https://doi.org/10.1183/09031936.00063109CrossRefGoogle Scholar
  4. 4.
    Van Schil PE, Opitz I, Weder W et al. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014;44(3):754–64.  https://doi.org/10.1183/09031936.00207213CrossRefGoogle Scholar
  5. 5.
    Carbone M, Ly BH, Dodson RF et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227(1):44–58.  https://doi.org/10.1002/jcp.22724CrossRefGoogle Scholar
  6. 6.
    Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243–60.  https://doi.org/10.1097/JTO.0000000000000630CrossRefGoogle Scholar
  7. 7.
    Kitajima K, Doi H, Kuribayashi K et al. Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. Eur J Radiol. 2017;86:176–83.  https://doi.org/10.1016/j.ejrad.2016.11.019CrossRefGoogle Scholar
  8. 8.
    Sugarbaker DJ, Gill RR, Yeap BY et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955–63.  https://doi.org/10.1016/j.jtcvs.2012.12.037CrossRefGoogle Scholar
  9. 9.
    Cao C, Tian D, Park J et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5.  https://doi.org/10.1016/j.lungcan.2013.11.026CrossRefGoogle Scholar
  10. 10.
    Schwartz RM, Watson A, Wolf A et al. The impact of surgical approach on quality of life for pleural malignant mesothelioma. Ann Transl Med. 2017;5(11):230.  https://doi.org/10.21037/atm.2017.03.41CrossRefGoogle Scholar
  11. 11.
    Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg. 2014;62(9):516–21.  https://doi.org/10.1007/s11748-014-0389-7CrossRefGoogle Scholar
  12. 12.
    Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472–80.  https://doi.org/10.1016/j.athoracsur.2014.09.056CrossRefGoogle Scholar
  13. 13.
    Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1(2):175–6CrossRefGoogle Scholar
  14. 14.
    Raskin J, Surmont V, Cornelissen R et al. A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Transl Lung Cancer Res. 2018;7(5):593–8.  https://doi.org/10.21037/tlcr.2018.05.07CrossRefGoogle Scholar
  15. 15.
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.  https://doi.org/10.1200/JCO.2003.11.136CrossRefGoogle Scholar
  16. 16.
    van Meerbeeck JP, Gaafar R, Manegold C et al et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9.  https://doi.org/10.1200/JCO.20005.14.589CrossRefGoogle Scholar
  17. 17.
    Zalcman G, Mazieres J, Margery J et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14.  https://doi.org/10.1016/S0140-6736(15)01238-6CrossRefGoogle Scholar
  18. 18.
    Mancuso MR, Neal JW. Novel systemic therapy against malignant pleural mesothelioma. Transl Lung Cancer Res. 2017;6(3):295–314.  https://doi.org/10.21037/tlcr.2017.06.01CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Laura V. Klotz
    • 1
    Email author
  • Florian Eichhorn
    • 1
  • Hauke Winter
    • 1
  • Martin E. Eichhorn
    • 1
  1. 1.Chirurgische Abteilung, Thoraxklinik HeidelbergUniversitätsklinikum HeidelbergHeidelbergDeutschland

Personalised recommendations